WASHINGTON--(BUSINESS WIRE)--The Global Alzheimer's Platform Foundation® (GAP) – which is focused on global game-changing dementia research – has chosen Scotland to host the Bio-Hermes Biomarker Data Challenge 2024, a research competition using the most comprehensive set of dementia biomarker data from ground-breaking early blood testing studies for Alzheimer’s disease. Researchers at the Universities of Glasgow and St. Andrews, under the auspices of the Scottish Funding Council’s Brain Health ARC, have launched a first-of-its-kind open access data competition to encourage just about any researcher, from any field, to use the information, with the hope of attracting bold ideas and breakthroughs in the fight against this devastating disease. The data for the challenge came from GAP’s Bio-Hermes study, which brought together the world’s leading digital and traditional cognitive assessment companies along with leading pharmaceutical partners to study cutting edge blood tests, brain scans and other tests for the diagnosis of dementia

SpeechDx, supported by the ADDF's Diagnostic Accelerator, invites industry, biotech and academic leaders to create a new class of digital biomarkersSpeechDx speech and clinical data from each individual will be paired and, ultimately, harmonized across all clinical sitesNEW YORK, Oct. 23, 2023 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation's (ADDF) Diagnostic Accelerator (DxA) today announced the launch of SpeechDx, the first longitudinal study aimed at creating the largest repository of speech and voice data to help accelerate the detection, diagnosis and monitoring of Alzheimer's disease. Recorded voice samples from the study will be paired with clinical and biomarker data that can be leveraged by academic, biotech, and industry partners to develop algorithms for the creation of new speech biomarkers.Scientific literature has shown subtle changes in speech and language patterns can indicate and predict cognitive decline associated with Alzheimer's, but to-date, tools have struggled to systematically capture these alterations. Recent technological advancements in conjunction with the boom in artificial intelligence and machine learning have enabled us to record these difficult-to-detect changes, thus setting the ground for the use of speech and voice as a new class of digital biomarkers for Alzheimer's."Speech is a complex cognitive process that contains important information about how your brain is functioning and scientific evidence shows us speech may hold the key to early, accurate, and non-invasive detection of Alzheimer's disease," says Howard Fillit, MD, Co-Founder and Chief Science Officer of the ADDF. "This study will help develop and validate voice-based biomarkers, expanding our existing arsenal of neuroimaging, peripheral blood, and digital biomarkers—all of which are crucial to delivering the right drugs to the right patients at the right time."SpeechDx is poised to develop a paired voice and clinical database that will provide the research community with harmonized data needed to generate speech-based diagnostic algorithms. These efforts will not only expand the existing portfolio of peripheral and digital biomarkers, but also further the DxA's vision to accelerate the development of non-invasive and accessible biomarkers and diagnostic tools for the early detection of Alzheimer's."To our knowledge, SpeechDx will comprise the largest-in-size, and longest-in-duration, curated repository of voice and clinical ground truth in dementia research," said Lampros Kourtis, PhD, DxA SpeechDx Program Manager at Gates Ventures

NEW YORK-September 27, 2023-The Alzheimer's Drug Discovery Foundation (ADDF) announced today a new partnership through its Diagnostics Accelerator (DxA) with the Alzheimer's Disease Data Initiative (ADDI), which will facilitate the sharing of Alzheimer's research data through the ADDI's data sharing and analysis platform, the AD Workbench.